Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 2922 (Fomivirsen) plus Ganciclovir for CMV Retinitis
NCT00002156Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fomivirsen in cytomegalovirus retinitis (2 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Time to progression of CMV retinitis and Safety and Adverse Events. Status: completed.
02
Drugs
fomivirsen
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00002156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002156.